View More View Less
  • 1 IV. Tüdőgyógyászati Osztály, Országos Korányi TBC és Pulmonológiai Intézet, 1529, Budapest, Pihenő u. 1.
  • 2 XI. Tüdőgyógyászati Osztály, Országos Korányi TBC és Pulmonológiai Intézet, Budapest
  • 3 Tumorbiológiai Osztály, Országos Korányi TBC és Pulmonológiai Intézet, Budapest
Restricted access

Absztrakt

Bár a sebészi reszekció, a platina-alapú kemoterápiás kombinációk és a sugárterápia javítottak a túlélési eredményeken, a nem kissejtes tüdőrák (NSCLC) túlélésének növekedési görbéje plató fázisához érkezett. Az új terápiás lehetőségek közé tartoznak a molekuláris célzott terápiák, ezeken belül a tumorok érhálózatára ható szerek. Jelenleg a bevacizumab – mely egy a vaszkuláris endotheliális növekedési faktor (VEGF) elleni rekombináns, monoklonális antitest – a klinikai fejlesztések legelőrehaladottabb stádiumban lévő gyógyszere. Ugyanakkor más célzott érellenes szerek is – beleértve a VDA-kat (vascular disrupting agents) és különféle kis molekulájú tirozinkináz-inhibitorokat – reménykeltők voltak a preklinikai és klinikai vizsgálatokban. Jelen közleményünkben áttekintjük az NSCLC-ben önmagukban vagy kemoterápiával kombináltan alkalmazható antivaszkuláris terápiás stratégiákat.

  • 1. A Aicher C Heeschen C Mildner-Rihm 2003 Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells Nat Med 9 1370 1376.

    • Search Google Scholar
    • Export Citation
  • 2. Amin DN , Bielenberg DR, Lifshits E, et al. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 18 Mar, 2008 (Epub ahead of print).

    • Search Google Scholar
    • Export Citation
  • 3. T Asahara T Murohara A Sullivan 1997 Isolation of putative progenitor endothelial cells for angiogenesis Science 275 964 967.

  • 4. P Baluk H Hashizume DM McDonald 2005 Cellular abnormalities of blood vessels as targets in cancer Curr Opin Genet Dev 15 102 111.

  • 5. LE Benjamin D Golijanin A Itin 1999 Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J Clin Invest 103 159 165.

    • Search Google Scholar
    • Export Citation
  • 6. P Bonomi 2002 Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer Semin Oncol 29 78 86.

  • 7. T Browder CE Butterfield BM Kräling 2000 Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 1878 1886.

    • Search Google Scholar
    • Export Citation
  • 8. LA Byers JV Heymach 2007 Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer Clin Lung Cancer 8 Suppl 2 S79 85.

    • Search Google Scholar
    • Export Citation
  • 9. DJ Chaplin GR Pettit SA Hill 1999 Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate Anticancer Res 19 189 195.

    • Search Google Scholar
    • Export Citation
  • 10. JJ Chen PL Yao A Yuan 2003 Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer Clin Cancer Res 9 729 737.

    • Search Google Scholar
    • Export Citation
  • 11. M Decaussin H Sartelet C Robert 1999 Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival J Pathol 188 369 377.

    • Search Google Scholar
    • Export Citation
  • 12. C Delbaldo S Michiels N Syz 2004 Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis JAMA 292 470 484.

    • Search Google Scholar
    • Export Citation
  • 13. P Delmotte B Martin M Paesmans 2002 VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis Rev Ma Respir 19 577 584.

    • Search Google Scholar
    • Export Citation
  • 14. B Dome J Dobos J Tovari 2008 Circulating bone marrow-derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease Cytometry A 73 186 193.

    • Search Google Scholar
    • Export Citation
  • 15. B Dome MJ Hendrix S Paku 2007 Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications Am J Pathol 170 1 15.

    • Search Google Scholar
    • Export Citation
  • 16. B Dome J Timar J Dobos 2006 Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer Cancer Res 66 7341 7347.

    • Search Google Scholar
    • Export Citation
  • 17. A Dowlati R Gray DH Johnson 2006 Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel + bevacizumab in advanced non-small cell lung cancer (NSCLC) J Clin Oncol 24S 7027.

    • Search Google Scholar
    • Export Citation
  • 18. J Drevs U Zirrgiebel CI Schmidt-Gersbach 2005 Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials Ann Oncol 16 558 565.

    • Search Google Scholar
    • Export Citation
  • 19. DG Duda RK Jain CG Willett 2007 Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers J Clin Oncol 25 4033 4042.

    • Search Google Scholar
    • Export Citation
  • 20. LM Ellis 2004 Epidermal growth factor receptor in tumor angiogenesis Hematol Oncol Clin North Am 18 1007 1021.

  • 21. G Fontanini L Boldrini S Chinè 1999 Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas Br J Cancer 79 363 369.

    • Search Google Scholar
    • Export Citation
  • 22. G Fontanini S Vignati L Boldrini 1997 Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma Clin Cancer Res 3 861 865.

    • Search Google Scholar
    • Export Citation
  • 23. E Fox JM Maris BC Widemann 2006 A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors Clin Cancer Res 12 4882 4887.

    • Search Google Scholar
    • Export Citation
  • 24. K Fujimoto T Abe NL Müller 2003 Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging: correlation with tumor vascularity and prognosis Radiology 227 786 793.

    • Search Google Scholar
    • Export Citation
  • 25. S Fujita S Nagamachi R Nishii 2006 Relationship between cancer cell proliferation, tumour angiogenesis and 201Tl uptake in non-small cell lung cancer Nucl Med Commun 27 989 997.

    • Search Google Scholar
    • Export Citation
  • 26. G Furstenberger R von Moos R Lucas 2006 Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer Br J Cancer 94 524 531.

    • Search Google Scholar
    • Export Citation
  • 27. E Garanger D Boturyn P Dumy 2007 Tumor targeting with RGD peptide ligands – design of new molecular conjugates for imaging and therapy of cancers Anticancer Agents Med Chem 7 552 558.

    • Search Google Scholar
    • Export Citation
  • 28. U Gatzemeier G Blumenschein F Fosella 2006 Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma J Clin Oncol 24 18S 7002.

    • Search Google Scholar
    • Export Citation
  • 29. JA Gollob S Wilhelm C Carter SL Kelley 2006 Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway Semin Oncol 33 392 406.

    • Search Google Scholar
    • Export Citation
  • 30. MS Gordon K Margolin M Talpaz 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 843 850.

    • Search Google Scholar
    • Export Citation
  • 31. GD Goss S Laurie F Shepherd 2007 Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group J Clin Oncol 25 18S 7649.

    • Search Google Scholar
    • Export Citation
  • 32. R Govindan N Page D Morgensztern 2006 Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 4539 4544.

    • Search Google Scholar
    • Export Citation
  • 33. J Guo K Higashi Y Ueda 2006 Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas J Nucl Med 47 419 425.

    • Search Google Scholar
    • Export Citation
  • 34. IE Haines GL Miklos A Rossi 2008 Paclitaxel plus bevacizumab for metastatic breast cancer N Eng J Med 358 1637 1638.

  • 35. H Han JF Silverman TS Santucci 2001 Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis Ann Surg Oncol 8 72 79.

    • Search Google Scholar
    • Export Citation
  • 36. KR Hande A Hagey J Berlin 2006 The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study Clin Cancer Res 12 2834 2840.

    • Search Google Scholar
    • Export Citation
  • 37. RS Herbst VJ O'Neill L Fehrenbacher 2007 Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer J Clin Oncol 25 4743 4750.

    • Search Google Scholar
    • Export Citation
  • 38. J Heymach L Paz-Ares F De Braud 2007 Randomized phase II study of vandetanib alone or in combination with carboplatin and paclitaxel as first-line treatment for advanced non-small cell lung cancer (NSCLC) J Clin Oncol 25 18S 7544.

    • Search Google Scholar
    • Export Citation
  • 39. JV Heymach BE Johnson D Prager 2007 Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer J Clin Oncol 25 4270 4277.

    • Search Google Scholar
    • Export Citation
  • 40. W Hilbe S Dirnhofer F Oberwasserlechner 2004 CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer J Clin Pathol 57 965 969.

    • Search Google Scholar
    • Export Citation
  • 41. A Hirata S Ogawa T Kometani 2002 ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res 62 2554 2560.

    • Search Google Scholar
    • Export Citation
  • 42. JW Ho RW Pang C Lau 2006 Significance of circulating endothelial progenitor cells in hepatocellular carcinoma Hepatology 44 836 843.

    • Search Google Scholar
    • Export Citation
  • 43. http://clinicaltrials.gov/ct2/show/NCT00073151?term=ABT-751+lung&rank=2.

  • 44. http://clinicaltrials.gov/ct2/show/NCT00113438?term=ca4p&rank=1.

  • 45. http://clinicaltrials.gov/ct2/show/NCT00297089?term=ABT-751+lung&rank=3.

  • 46. http://clinicaltrials.gov/ct2/show/NCT00354562?term=ABT-751+lung&rank=1.

  • 47. http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=11207.

  • 48. http://www.press.bayer.com/baynews/baynews.nsf/id/7F2163C8C6C18519C12573F30051050E?Open&ccm=001.

  • 49. J Hu F Bianchi M Ferguson 2005 Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer Oncogene 24 1212 1219.

    • Search Google Scholar
    • Export Citation
  • 50. CA Hudis 2005 Clinical implications of antiangiogenic therapies Oncology (Williston Park) 19 4 Suppl 3 26 31.

  • 51. H Hurwitz L Fehrenbacher W Novotny 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342.

    • Search Google Scholar
    • Export Citation
  • 52. C Igreja M Courinha AS Cachaco 2007 Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients Haematologica 92 469 477.

    • Search Google Scholar
    • Export Citation
  • 53. A Iwasaki M Kuwahara Y Yoshinaga T Shirakusa 2004 Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC Eur J Cardiothorac Surg 25 443 448.

    • Search Google Scholar
    • Export Citation
  • 54. RK Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 987 989.

  • 55. RK Jain DG Duda JW Clark JS Loeffler 2006 Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat Clin Pract Oncol 3 24 40.

    • Search Google Scholar
    • Export Citation
  • 56. DH Johnson L Fehrenbacher WF Novotny 2004 Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2184 2191.

    • Search Google Scholar
    • Export Citation
  • 57. F Kabbinavar HI Hurwitz L Fehrenbacher 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65.

    • Search Google Scholar
    • Export Citation
  • 58. NB Leighl L Paz-Arez JL Douillard 2005 Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18 J Clin Oncol 23 2831 2839.

    • Search Google Scholar
    • Export Citation
  • 59. B Li EE Sharpe AB Maupin 2006 VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization FASEB J 20 1495 1497.

    • Search Google Scholar
    • Export Citation
  • 60. X Li M Tjwa L Moons 2005 Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors J Clin Invest 115 118 127.

    • Search Google Scholar
    • Export Citation
  • 61. Y Li ZG Yang TW Chen 2008 Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT Lung Cancer 61 44 53.

    • Search Google Scholar
    • Export Citation
  • 62. B Liu T Barrett P Choyke 2006 A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC) J Clin Oncol 24 18S 17119.

    • Search Google Scholar
    • Export Citation
  • 63. J Llevadot S Murasawa Y Kureish 2001 HMG-CoA reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cells J Clin Invest 108 399 405.

    • Search Google Scholar
    • Export Citation
  • 64. F Loupakis A Falcone G Masi 2007 Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity J Clin Oncol 25 1816 1818.

    • Search Google Scholar
    • Export Citation
  • 65. SH Ma K Xu ZW Xiao 2007 Peripheral lung cancer: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and cyclin D1 expression Clin Imaging 31 165 177.

    • Search Google Scholar
    • Export Citation
  • 66. C Manegold J von Pawel P Zatloukal 2007 Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 J Clin Oncol 25 18S 7514.

    • Search Google Scholar
    • Export Citation
  • 67. R Masood J Cai T Zheng 2001 Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors Blood 98 1904 1913.

    • Search Google Scholar
    • Export Citation
  • 68. M Massa V Rosti I Ramajoli 2005 Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia J Clin Oncol 23 5688 5695.

    • Search Google Scholar
    • Export Citation
  • 69. HJ Mauceri NN Hanna MA Beckett 1998 Combined effects of angiostatin and ionizing radiation in antitumour therapy Nature 394 287 291.

    • Search Google Scholar
    • Export Citation
  • 70. MJ McKeage 2006 Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) J Clin Oncol 24 18S 7102.

    • Search Google Scholar
    • Export Citation
  • 71. KD Miller CJ Sweeney GW Sledge Jr 2001 Redefining the target: chemotherapeutics as antiangiogenics J Clin Oncol 19 1195 1206.

  • 72. MA Moore K Hattori B Heissig 2001 Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1 Ann NY Acad Sci 938 36 47.

    • Search Google Scholar
    • Export Citation
  • 73. R Murata DW Siemann J Overgaard MR Horsman 2001 Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid Radiat Res 156 503 509.

    • Search Google Scholar
    • Export Citation
  • 74. RB Natale D Bodkin R Govindan 2006 ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part double-blind randomized phase II trial J Clin Oncol 24 18S 7000.

    • Search Google Scholar
    • Export Citation
  • 75. AM O'Farrell TJ Abrams HA Yuen 2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 3597 3605.

    • Search Google Scholar
    • Export Citation
  • 76. M Olivero M Rizzo R Madeddu 1996 Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas Br J Cancer 74 1862 1868.

    • Search Google Scholar
    • Export Citation
  • 77. Y Ozawa NH Sugi T Nagasu 2001 E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo Eur J Cancer 37 2275 2282.

    • Search Google Scholar
    • Export Citation
  • 78. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108.

  • 79. E Passalidou M Trivella N Singh 2002 Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas Br J Cancer 86 244 249.

    • Search Google Scholar
    • Export Citation
  • 80. DM Patterson GJ Rustin 2007 Vascular damaging agents Clin Oncol (R Coll Radiol) 19 443 456.

  • 81. AM Petit J Rak MC Hung 1997 Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am J Pathol 151 1523 1530.

    • Search Google Scholar
    • Export Citation
  • 82. F Pezzella U Pastorino E Tagliabue 1997 Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis Am J Pathol 151 1417 1423.

    • Search Google Scholar
    • Export Citation
  • 83. DG Pfister DH Johnson CG Azzoli 2004 American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 330 353.

    • Search Google Scholar
    • Export Citation
  • 84. A Pircher CM Kähler S Skvortsov 2008 Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance Oncol Rep 19 345 352.

    • Search Google Scholar
    • Export Citation
  • 85. JM Provenzale 2007 Imaging of angiogenesis: clinical techniques and novel imaging methods AJR Am J Roentgenol 188 11 23.

  • 86. M Relf S LeJeune PA Scott 1997 Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res 57 963 969.

    • Search Google Scholar
    • Export Citation
  • 87. GJ Riely VA Miller 2007 Vascular endothelial growth factor trap in non small cell lung cancer Clin Cancer Res 13 4623 4627.

  • 88. T Sánchez-Elsner LM Botella B Velasco 2002 Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways J Biol Chem 277 43799 43808.

    • Search Google Scholar
    • Export Citation
  • 89. A Sandler R Gray MC Perry 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550.

    • Search Google Scholar
    • Export Citation
  • 90. M Santimaria G Moscatelli GL Viale 2003 Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer Clin Cancer Res 9 571 579.

    • Search Google Scholar
    • Export Citation
  • 91. M Santoro RM Melillo F Carlomagno 2002 Molecular mechanisms of RET activation in human cancer Ann NY Acad Sci 963 116 121.

  • 92. JH Schiller D Harrington CP Belani 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92 98.

    • Search Google Scholar
    • Export Citation
  • 93. JH Schiller T Larson SI Ou 2007 Efficacy and safety of axitinib (AG-013736; AG) in patients with advanced non-small cell lung cancer (NSCLC): A phase II trial J Clin Oncol 25 18S 7507.

    • Search Google Scholar
    • Export Citation
  • 94. FH Seeger J Haendeler DH Walter 2005 p38 mitogen-activated protein kinase downregulates endothelial progenitor cells Circulation 111 1184 1191.

    • Search Google Scholar
    • Export Citation
  • 95. G Serini D Valdembri F Bussolino 2006 Integrins and angiogenesis: a sticky business Exp Cell Res 312 651 658.

  • 96. T Seto M Higashiyama H Funai 2006 Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer Lung Cancer 53 91 96.

    • Search Google Scholar
    • Export Citation
  • 97. Y Shaked A Ciarrocchi M Franco 2006 Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 1785 1787.

    • Search Google Scholar
    • Export Citation
  • 98. FA Shepherd J Rodrigues Pereira T Ciuleanu 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132.

    • Search Google Scholar
    • Export Citation
  • 99. M Shiraga S Yano A Yamamoto 2002 Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines Cancer Res 62 5967 5973.

    • Search Google Scholar
    • Export Citation
  • 100. DW Siemann MC Bibby GG Dark 2005 Differentiation and definition of vascular-targeted therapies Clin Cancer Res 11 416 420.

  • 101. DW Siemann E Mercer S Lepler AM Rojiani 2002 Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy Int J Cancer 99 1 6.

    • Search Google Scholar
    • Export Citation
  • 102. BG Siim AE Lee S Shalal-Zwain 2003 Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) Cancer Chemother Pharmacol 51 43 52.

    • Search Google Scholar
    • Export Citation
  • 103. MA Socinski S Novello JM Sanchez 2006 Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial J Clin Oncol 24 18S 7001.

    • Search Google Scholar
    • Export Citation
  • 104. K Strehlow N Werner J Berweiler 2003 Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation Circulation 107 3059 3065.

    • Search Google Scholar
    • Export Citation
  • 105. CJ Sweeney KD Miller SE Sissons 2001 The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 61 3369 3372.

    • Search Google Scholar
    • Export Citation
  • 106. T Tamura H Minami Y Yamada 2006 A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors J Thoracic Oncol 1 1002 1009.

    • Search Google Scholar
    • Export Citation
  • 107. F Tanaka S Ishikawa K Yanagihara 2002 Expression of angiopoietins and its clinical significance in non-small cell lung cancer Cancer Res 62 7124 7129.

    • Search Google Scholar
    • Export Citation
  • 108. N Thatcher A Chang P Parikh 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537.

    • Search Google Scholar
    • Export Citation
  • 109. Tímár J , Döme B. Antiangiogenic drugs and tyrosine kinases. Anticancer Agents Med Chem 2008 (in press).

  • 110. S Verma MA Kuliszewski SH Li 2004 C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease Circulation 109 2058 2067.

    • Search Google Scholar
    • Export Citation
  • 111. JM Vignaud B Marie N Klein 1994 The role of platelet-derived growth factor production by tumor-associated macrophages in tumor stroma formation in lung cancer Cancer Res 54 5455 5463.

    • Search Google Scholar
    • Export Citation
  • 112. SR Wedge DJ Ogilvie M Dukes 2002 ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645 4655.

    • Search Google Scholar
    • Export Citation
  • 113. A Wierzbowska T Robak A Krawczynska 2005 Circulating endothelial cells in patients with acute myeloid leukemia Eur J Haematol 75 492 497.

    • Search Google Scholar
    • Export Citation
  • 114. SM Wilhelm M Carter L Tang 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109.

    • Search Google Scholar
    • Export Citation
  • 115. CG Willett Y Boucher E di Tomaso 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145 147.

    • Search Google Scholar
    • Export Citation
  • 116. CG Willett Y Boucher DG Duda 2005 Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J Clin Oncol 23 8136 8139.

    • Search Google Scholar
    • Export Citation
  • 117. www.oxigene.com/vascular/vascular.asp#ZYBRESTAT.

  • 118. JC Yang L Haworth RM Sherry 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434.

    • Search Google Scholar
    • Export Citation
  • 119. KW Yee A Hagey S Verstovsek 2005 Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies Clin Cancer Res 11 6615 6624.

    • Search Google Scholar
    • Export Citation
  • 120. Y Yokoyama M Dhanabal AW Griffioen 2000 Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth Cancer Res 60 2190 2196.

    • Search Google Scholar
    • Export Citation
  • 121. H Zhang V Vakil M Braunstein 2005 Circulating endothelial progenitor cells in multiple myeloma: implications and significance Blood 105 3286 3294.

    • Search Google Scholar
    • Export Citation
  • 122. L Zhang J Chen Y Ke 2005 Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance World J Surg Oncol 3 68.

    • Search Google Scholar
    • Export Citation
  • 123. PP Zheng WC Hop TM Luider 2007 Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas Ann Neurol 62 40 48.

    • Search Google Scholar
    • Export Citation